The gene encoding PCSK9 was first identified and linked to the phenotype of familial
hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role …

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …

The recommendations listed in the present guideline are, whenever possible, evidence
based. An initial extensive evidence review, which included literature derived from research …

Background Pharmacologic inhibitors of proprotein convertase subtilisin–kexin type 9
(PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease …

Aims To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous
familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally …

Background Statin intolerance limits many patients from achieving optimal low-density
lipoprotein cholesterol (LDL-C) concentrations. Current options for such patients include …

An increased risk of cardiovascular disease, independent of conventional risk factors, is
present even at minor levels of renal impairment and is highest in patients with end-stage …

Importance Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently
approved for lowering low-density lipoprotein cholesterol in heterozygous familial …

Background Despite the availability of effective drug therapies that reduce low‐density
lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important …

Aims We performed a network meta-analysis of randomized controlled trials (RCTs) in
patients with primary hypercholesterolaemia to compare the impact of proprotein convertase …